Casdin Capital

Casdin Capital is a New York-based investment firm distinguished by its fundamental research-driven approach to the life sciences and healthcare sectors. Founded by Eli Casdin, the firm employs a unique hybrid investment model, deploying capital across both public and private markets. This dual focus allows Casdin Capital to engage with companies at various stages of their lifecycle, from nascent private ventures to established public entities, providing a comprehensive and flexible investment strategy within the complex biotech and healthcare landscape.

The firm's investment philosophy is deeply rooted in scientific and industry expertise, aiming to identify and support companies poised for significant innovation and growth. Casdin Capital is known for its substantial capital deployment, evidenced by the closing of its latest fund in March 2022, which raised an impressive $1.1 billion. This significant capital base enables the firm to make meaningful investments, with typical first checks for private companies ranging from $25 million to $100 million. They often take on lead or co-lead investor roles in funding rounds, demonstrating a commitment to actively shaping the trajectory of their portfolio companies.

Casdin Capital's portfolio spans a wide array of life science sub-sectors, including genomics, cell and gene therapy, drug discovery platforms, and diagnostics. They seek out companies that are leveraging cutting-edge science and technology to address unmet medical needs or revolutionize healthcare delivery. Their strategic involvement extends beyond capital, often providing operational and strategic guidance to help founders and management teams scale their innovations. This hands-on approach, combined with their deep sector knowledge, positions Casdin Capital as a significant player in advancing the life sciences ecosystem.